5,6-dimethyl-2H,4H-1,3-oxazine-2,4-dione | 61736-31-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 5,6-dimethyl-2H,4H-1,3-oxazine-2,4-dione
• 英文别名: 5,6-dimethyl-1,3-oxazine-2,4(3H)-dione；5,6-dimethyl-[1,3]oxazine-2,4-dione；5,6-Dimethyl-1,3-oxazin-2,4(3H)-dion；5,6-Dimethyl-2H-1,3-oxazine-2,4(3H)-dione；5,6-dimethyl-1,3-oxazine-2,4-dione
• CAS: 61736-31-0
• 化学式: C₆H₇NO₃
• 分子量: 141.126
• InChiKey: FYLUMEIYAHWCRK-UHFFFAOYSA-N

物化性质

• 熔点：
  160-162 °C(Solv: ethyl ether (60-29-7))
• 密度：
  1.218±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5,6-dimethyl-2H,4H-1,3-oxazine-2,4-dione 在 sodium hydroxide 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.5h， 生成 3-<(3,4-dichlorophenyl)methyl>-3,6-dihydro-4,5-dimethyl-2,6-dioxo-1(2H)-pyrimidineacetic acid
  参考文献：
  名称：

  Quinazolineacetic acids and related analogs as aldose reductase inhibitors

  摘要：

  A variety of 2,4-dioxoquinazolineacetic acids (10, 11) were synthesized as hybrids of the known aldose reductase inhibitors alrestatin (8), ICI-105,552 (9), and ICI-128,436 (2) and evaluated for their ability to inhibit partially purified bovine lens aldose reductase (in vitro) and their effectiveness to decrease galactitol accumulation in the 4-day galactosemic rat model (in vivo). In support to SAR studies, related analogues pyrimidinediones (12), dihydroquinazolones (13), and indazolidinones (14, 15) were synthesized and tested in the in vitro and in vivo assays. All prepared compounds (10-15) have shown a high level of in vitro activity (IC50 approximately 10(-6) to 4 x 10(-8) M). However, only the 2,4-quinazolinedione analogues 10 and 11, with similar N-aralkyl substitution found in 2 and 9, have exhibited good oral potency. The remaining compounds were either inactive or had only a marginal in vivo activity. The structure-activity data support the presence of a secondary hydrophobic pocket in the vicinity of the primary lipophilic region of the enzyme.

  DOI：

  10.1021/jm00108a038
• 作为产物：
  描述：

  2,2,5,6-四甲基-4H-1,3-二氧杂-4-酮 、 氨基甲酸乙酯 以 均三甲苯 为溶剂， 反应 1.0h， 以21%的产率得到5,6-dimethyl-2H,4H-1,3-oxazine-2,4-dione
  参考文献：
  名称：

  Sato, Masayuki; Ogasawara, Hiromichi; Komatsu, Sachiko, Chemical and pharmaceutical bulletin, 1984, vol. 32, # 10, p. 3848 - 3856

  摘要：

  DOI：

文献信息

• Ahmed,S. et al., Journal of the Chemical Society. Perkin transactions I, 1976, p. 1969 - 1975
  作者：Ahmed,S. et al.

  DOI：——

  日期：——
• SATO, MASAYUKI;OGASAWARAI, HIROMICHI;KOMATSU, SACHIKO;KATO, TETSUZO, CHEM. AND PHARM. BULL., 1984, 32, N 10, 3848-3856
  作者：SATO, MASAYUKI、OGASAWARAI, HIROMICHI、KOMATSU, SACHIKO、KATO, TETSUZO

  DOI：——

  日期：——
• ANTI-INFECTIVE AGENTS
  申请人：Abbott Laboratories

  公开号：EP1560827A1

  公开（公告）日：2005-08-10
• [EN] ANTI-INFECTIVE AGENTS<br/>[FR] AGENTS ANTI-INFECTIEUX
  申请人：ABBOTT LAB

  公开号：WO2004041818A1

  公开（公告）日：2004-05-21

  The present invention provides an HCV polymerase inhibiting compound having the formula (I) and a composition comprising a therapeutically effective amount of said compound. The present invention also provides a method for inhibiting hepatitis C virus (HCV) polymerase, a method for inhibiting HCV viral replication, and a method for treating or preventing HCV infection. Processes for making said compounds, and synthetic intermediates employed in said processes, are also provided.
• Sato, Masayuki; Ogasawara, Hiromichi; Komatsu, Sachiko, Chemical and pharmaceutical bulletin, 1984, vol. 32, # 10, p. 3848 - 3856
  作者：Sato, Masayuki、Ogasawara, Hiromichi、Komatsu, Sachiko、Kato, Tetsuzo

  DOI：——

  日期：——